65,437 trials
NHL · Non Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma
Primary: Number of Participants Experiencing Dose Limiting Toxicity Events — 0; 0; 0 Participants
Postoperative Pain
Primary: Pain as Measured by the Visual-analog Scale — 1 units on a scale
Opioid-use Disorder
Primary: Linkage to Medication for Opioid Use Disorder (MOUD) — 25; 47; 113; 89 Participants
Cytomegalovirus (CMV)
Primary: Percentage of Participants Who Achieved Confirmed Clearance of Plasma CMV Deoxyribose Nucleic Acid (DNA) at Week 8 — 68.3 percentage of participants
Sepsis
Primary: Delta Curve Between Calculated GFR and GFR Measured by Iohexol at Baseline — 91.5; 88.3; 93.6; 90.0 ml/min/1.73m2 — p=<0.05
Medullary Thyroid Cancer (MTC)
Primary: Calcitonin Growth Rate — -2.53; -2.49 days^-1 — p=0.3760
Malignant Melanoma
Primary: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST…
Alzheimer Disease
Primary: Change in fMRI — 11 Participants
Positron-Emission Tomography · Metastatic Solid Tumors
Primary: Correlation of ⁸⁹Zr-Df-IAB22M2C Uptake in Biopsied Tumors With CD8+ Cell Measurement by Immunohistochemistry (IHC) — 0.3902; 0.7848 r
Constipation Chronic Idiopathic
Primary: CSBM 1 Success Rate — 24; 17 Participants
Paraplegia · Tetraplegia · Paralysis
Primary: Electromyography — 0.00017507; 0.00006740 volts
Myopia · Hyperopia
Primary: Lens Handling on Removal — 84; 89 score on a scale
Sleep · Obesity · Sleep Restriction
Primary: Endpoint Fat Volume — 24.0; 24.2 Liter
Sleep Apnea, Obstructive · Brain Injuries, Traumatic
Primary: Narrative Evaluation of Intervention Interview (Post-intervention Qualitative Interview) — 4 Themes
Presbyopia
Primary: Lens Handling for Removal — 94; 95 score on a scale